{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:26Z","timestamp":1791908186818,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-025-01856-w","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:16:57Z","timestamp":1738581417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of biochemical and structural response to medical therapy in patients with active acromegaly following surgery: a real-world perspective"],"prefix":"10.1186","volume":"25","author":[{"given":"Maryam","family":"Rafieemanesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manizhe Ataee","family":"Kachuee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Zare","family":"Mehrjardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Khajavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ghorbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Mohajeri-Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Hashemi-Madani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad E.","family":"Khamseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"issue":"1","key":"1856_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LF, Giustina A, Melmed S, Chanson P, Pereira AM, et al. Acromegaly Nat Reviews Disease Primers. 2019;5(1):20.","journal-title":"Acromegaly Nat Reviews Disease Primers"},{"issue":"4","key":"1856_CR2","doi-asserted-by":"publisher","first-page":"e937","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BM, Boguszewski C, et al. A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metabolism. 2020;105(4):e937\u201346.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"1","key":"1856_CR3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","volume":"40","author":"MR Gadelha","year":"2019","unstructured":"Gadelha MR, Kasuki L, Lim DS, Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. 2019;40(1):268\u2013332.","journal-title":"Endocr Rev"},{"issue":"9","key":"1856_CR4","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JA, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Reviews Endocrinol. 2018;14(9):552\u201361.","journal-title":"Nat Reviews Endocrinol"},{"key":"1856_CR5","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","volume":"159","author":"C-J Chen","year":"2017","unstructured":"Chen C-J, Ironside N, Pomeraniec IJ, Chivukula S, Buell TJ, Ding D, et al. Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications. Acta Neurochir. 2017;159:2193\u2013207.","journal-title":"Acta Neurochir"},{"key":"1856_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BM, Freda PU, Gadelha MR, Giustina A, Katznelson L, et al. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021;24:1\u201313.","journal-title":"Pituitary"},{"issue":"11","key":"1856_CR7","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","volume":"107","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grang\u00e9 L, Schillo F, et al. Predictive Factors of Somatostatin Receptor Ligand response in Acromegaly-A prospective study. J Clin Endocrinol Metab. 2022;107(11):2982\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1856_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G, Pivonello R. Resistance to somatostatin analogs in acromegaly. Endocr Rev. 2011;32(2):247\u201371.","journal-title":"Endocr Rev"},{"issue":"6","key":"1856_CR9","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/cen.13595","volume":"88","author":"L Kasuki","year":"2018","unstructured":"Kasuki L, Dalmolin MD, Wildemberg LE, Gadelha MR. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. Clin Endocrinol. 2018;88(6):889\u201395.","journal-title":"Clin Endocrinol"},{"issue":"1","key":"1856_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1097\/RCT.0000000000001249","volume":"46","author":"C-X Liu","year":"2022","unstructured":"Liu C-X, Wang S-Z, Heng L-J, Han Y, Ma Y-H, Yan L-F, et al. Predicting subtype of growth hormone pituitary adenoma based on magnetic resonance imaging characteristics. J Comput Assist Tomogr. 2022;46(1):124\u201330.","journal-title":"J Comput Assist Tomogr"},{"key":"1856_CR11","doi-asserted-by":"publisher","first-page":"677919","DOI":"10.3389\/fendo.2021.677919","volume":"12","author":"F Nista","year":"2021","unstructured":"Nista F, Corica G, Castelletti L, Campana C, Zoppoli G, Ferone D, et al. Clinical and radiological predictors of biochemical response to first-line treatment with somatostatin receptor ligands in acromegaly: a real-life perspective. Front Endocrinol. 2021;12:677919.","journal-title":"Front Endocrinol"},{"issue":"4","key":"1856_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","volume":"122","author":"AS Micko","year":"2015","unstructured":"Micko AS, W\u00f6hrer A, Wolfsberger S, Knosp E. Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification. J Neurosurg. 2015;122(4):803\u201311.","journal-title":"J Neurosurg"},{"issue":"2","key":"1856_CR13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1530\/ERC-14-0305","volume":"22","author":"I Potorac","year":"2015","unstructured":"Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, et al. Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer. 2015;22(2):169\u201377.","journal-title":"Endocr Relat Cancer"},{"key":"1856_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","volume":"19","author":"A Obari","year":"2008","unstructured":"Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol. 2008;19:82\u201391.","journal-title":"Endocr Pathol"},{"issue":"4","key":"1856_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Reviews Endocr Metabolic Disorders. 2020;21(4):667\u201378.","journal-title":"Reviews Endocr Metabolic Disorders"},{"issue":"5","key":"1856_CR16","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1210\/jc.2013-3757","volume":"99","author":"JD Carmichael","year":"2014","unstructured":"Carmichael JD, Bonert VS, Nu\u00f1o M, Ly D, Melmed S. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014;99(5):1825\u201333.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1856_CR17","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Uygur MM, Frara S, Barkan A, Biermasz NR, Chanson P, et al. Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE). Pituitary. 2024;27(4):381\u20138.","journal-title":"Pituitary"},{"issue":"5","key":"1856_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1210\/jc.2010-2443","volume":"96","author":"L Sandret","year":"2011","unstructured":"Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96(5):1327\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1856_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11102-023-01360-1","volume":"27","author":"A Giustina","year":"2024","unstructured":"Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27(1):7\u201322.","journal-title":"Pituitary"},{"issue":"2","key":"1856_CR20","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol. 2009;161(2):331\u20138.","journal-title":"Eur J Endocrinol"},{"key":"1856_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/jcm11216508","volume":"11","author":"F Bioletto","year":"2022","unstructured":"Bioletto F, Berton AM, Prencipe N, Varaldo E, Bona C, Grottoli S. Markers of aggressiveness in Pituitary tumors: Update and perspectives. J Clin Med. 2022;11:21.","journal-title":"J Clin Med"},{"issue":"Suppl 3","key":"1856_CR22","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.21037\/gs.2019.06.04","volume":"8","author":"F Tortora","year":"2019","unstructured":"Tortora F, Negro A, Grasso LFS, Colao A, Pivonello R, Splendiani A, et al. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas. Gland Surg. 2019;8(Suppl 3):S150\u20138.","journal-title":"Gland Surg"},{"issue":"11","key":"1856_CR23","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1530\/ERC-16-0356","volume":"23","author":"I Potorac","year":"2016","unstructured":"Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, et al. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-related Cancer. 2016;23(11):871\u201381.","journal-title":"Endocrine-related Cancer"},{"issue":"11","key":"1856_CR24","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1210\/jc.2010-0573","volume":"95","author":"M Puig-Domingo","year":"2010","unstructured":"Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metabolism. 2010;95(11):4973\u20138.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1856_CR25","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","volume":"16","author":"J Brzana","year":"2013","unstructured":"Brzana J, Yedinak CG, Gultekin SH, Delashaw JB, Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary. 2013;16:490\u20138.","journal-title":"Pituitary"},{"issue":"3","key":"1856_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1507\/endocrj.EJ11-0177","volume":"59","author":"M Kato","year":"2012","unstructured":"Kato M, Inoshita N, Sugiyama T, Tani Y, Shichiri M, Sano T, et al. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. Endocr J. 2012;59(3):221\u20138.","journal-title":"Endocr J"},{"key":"1856_CR27","doi-asserted-by":"crossref","unstructured":"Liu W, Xie L, He M, Shen M, Zhu J, Yang Y et al. Expression of somatostatin receptor 2 in somatotropinoma correlated with the short-term efficacy of somatostatin analogues. International journal of endocrinology. 2017;2017.","DOI":"10.1155\/2017\/9606985"},{"issue":"6","key":"1856_CR28","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1210\/jc.2008-1826","volume":"94","author":"LV Neto","year":"2009","unstructured":"Neto LV, Machado EO, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metabolism. 2009;94(6):1931\u20137.","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1856_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s11102-014-0574-9","volume":"18","author":"E Fernandez-Rodriguez","year":"2015","unstructured":"Fernandez-Rodriguez E, Casanueva F, Bernabeu I. Update on prognostic factors in acromegaly: is a risk score possible? Pituitary. 2015;18:431\u201340.","journal-title":"Pituitary"},{"issue":"5","key":"1856_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-15-0391","volume":"174","author":"F Gatto","year":"2016","unstructured":"Gatto F, Biermasz NR, Feelders RA, Kros JM, Dogan F, van der Lely A-J, et al. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol. 2016;174(5):651\u201362.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"1856_CR31","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1210\/jc.2009-2197","volume":"95","author":"SL Fougner","year":"2010","unstructured":"Fougner SL, Lekva T, Borota OC, Hald JK, Bollerslev J, Berg JP. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response. J Clin Endocrinol Metabolism. 2010;95(5):2334\u201342.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"2","key":"1856_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2265.1992.tb02304.x","volume":"37","author":"A Van der Lely","year":"1992","unstructured":"Van der Lely A, Harrls A, Lamberts S. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol. 1992;37(2):181\u20135.","journal-title":"Clin Endocrinol"},{"issue":"11","key":"1856_CR33","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1210\/jc.2005-0998","volume":"90","author":"S Bhayana","year":"2005","unstructured":"Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metabolism. 2005;90(11):6290\u20135.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"9","key":"1856_CR34","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1210\/clinem\/dgaa387","volume":"105","author":"EC Coopmans","year":"2020","unstructured":"Coopmans EC, Korevaar TI, van Meyel SW, Daly AF, Chanson P, Brue T, et al. Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metabolism. 2020;105(9):2964\u201374.","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"3","key":"1856_CR35","doi-asserted-by":"publisher","first-page":"R223","DOI":"10.1530\/JME-14-0011","volume":"52","author":"D Cuevas-Ramos","year":"2014","unstructured":"Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol. 2014;52(3):R223\u201340.","journal-title":"J Mol Endocrinol"},{"issue":"1\u20132","key":"1856_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2010.01.033","volume":"326","author":"M Theodoropoulou","year":"2010","unstructured":"Theodoropoulou M, Stalla GK, Spengler D. ZAC1 target genes and pituitary tumorigenesis. Mol Cell Endocrinol. 2010;326(1\u20132):60\u20135.","journal-title":"Mol Cell Endocrinol"},{"issue":"12","key":"1856_CR37","doi-asserted-by":"publisher","first-page":"4715","DOI":"10.1210\/en.2013-1672","volume":"154","author":"F Gatto","year":"2013","unstructured":"Gatto F, Feelders R, van der Pas R, Kros JM, Dogan F, van Koetsveld PM, et al. \u03b2-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly. Endocrinology. 2013;154(12):4715\u201325.","journal-title":"Endocrinology"},{"issue":"1","key":"1856_CR38","first-page":"822","volume":"13","author":"T Florio","year":"2008","unstructured":"Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13(1):822\u201340.","journal-title":"Front Biosci"},{"issue":"8","key":"1856_CR39","doi-asserted-by":"publisher","first-page":"102924","DOI":"10.1016\/j.arcmed.2023.102924","volume":"54","author":"M Marques-Pamies","year":"2023","unstructured":"Marques-Pamies M, Gil J, Jord\u00e0 M, Puig-Domingo M. Predictors of response to treatment with first-generation somatostatin receptor ligands in patients with acromegaly. Arch Med Res. 2023;54(8):102924.","journal-title":"Arch Med Res"},{"issue":"5","key":"1856_CR40","doi-asserted-by":"publisher","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","volume":"7","author":"A Giustina","year":"2012","unstructured":"Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE. 2012;7(5):e36411.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"1856_CR41","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1530\/EJE-09-0350","volume":"161","author":"M Buchfelder","year":"2009","unstructured":"Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Br\u00fcbach K, et al. The German ACROSTUDY: past and present. Eur J Endocrinol. 2009;161(Suppl 1):S3\u201310.","journal-title":"Eur J Endocrinol"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01856-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-025-01856-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-025-01856-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:17:02Z","timestamp":1738581422000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-025-01856-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,3]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1186\/s12902-025-01856-w","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,3]]},"assertion":[{"value":"15 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in line with the recommendations of the Declaration of Helsinki and written informed consent was obtained from all the patients for using the available data for research purposes. The ethics committee of the Iran University of Medical Sciences approved the study (ethical code IR.IUMS.REC.1401.963).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"30"}}